On Friday, Nektar Therapeutics (NASDAQ: NKTR) was 6.02% up from the session before settling in for the closing price of $21.75. A 52-week range for NKTR has been $6.48 – $37.38.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 25.49%. When this article was written, the company’s average yearly earnings per share was at -30.48%. With a float of $16.86 million, this company’s outstanding shares have now reached $17.30 million.
Let’s determine the extent of company efficiency that accounts for 61 employees. In terms of profitability, gross margin is 74.61%, operating margin of -131.01%, and the pretax margin is -147.55%.
Nektar Therapeutics (NKTR) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Nektar Therapeutics stocks. The insider ownership of Nektar Therapeutics is 2.55%, while institutional ownership is 56.83%. The most recent insider transaction that took place on May 19 ’25, was worth 7,177. In this transaction Chief R&D Officer of this company sold 10,712 shares at a rate of $0.67, taking the stock ownership to the 305,892 shares. Before that another transaction happened on May 19 ’25, when Company’s Chief Legal Officer sold 9,996 for $0.67, making the entire transaction worth $6,697. This insider now owns 314,296 shares in total.
Nektar Therapeutics (NKTR) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -2.65 earnings per share (EPS) during the time that was better than consensus figure (set at -3.09) by 0.44. Wall Street market experts anticipate that the next fiscal year will bring earnings of -3.41 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -30.48% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -16.71% during the next five years compared to 25.49% growth over the previous five years of trading.
Nektar Therapeutics (NASDAQ: NKTR) Trading Performance Indicators
You can see what Nektar Therapeutics (NKTR) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.61. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.32.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -8.72, a number that is poised to hit -2.80 in the next quarter and is forecasted to reach -11.99 in one year’s time.
Technical Analysis of Nektar Therapeutics (NKTR)
Looking closely at Nektar Therapeutics (NASDAQ: NKTR), its last 5-days average volume was 0.51 million, which is a drop from its year-to-date volume of 0.86 million. As of the previous 9 days, the stock’s Stochastic %D was 36.71%.
During the past 100 days, Nektar Therapeutics’s (NKTR) raw stochastic average was set at 53.70%, which indicates a significant increase from 38.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.46 in the past 14 days, which was lower than the 1.63 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.43, while its 200-day Moving Average is $14.99. However, in the short run, Nektar Therapeutics’s stock first resistance to watch stands at $24.02. Second resistance stands at $24.99. The third major resistance level sits at $25.99. If the price goes on to break the first support level at $22.05, it is likely to go to the next support level at $21.05. Now, if the price goes above the second support level, the third support stands at $20.08.
Nektar Therapeutics (NASDAQ: NKTR) Key Stats
There are 12,407K outstanding shares of the company, which has a market capitalization of 398.96 million. As of now, sales total 98,430 K while income totals -118,960 K. Its latest quarter income was 10,460 K while its last quarter net income were -50,880 K.
